Pfizer Q1 2026 Earnings Beat Estimates on Growth from Newer Drugs
Pfizer reported first-quarter revenue of $14.45 billion, a 5% year-over-year increase driven by growth in oncology and recently launched products despite declining sales for its COVID vaccine and antiviral pill. The company's results exceeded analyst expectations.
Tickers: $PFE
Topics: Financial Performance Oncology Drugs Pharmaceuticals Revenue Growth